HURATuHURA Biosciences, Inc.Signing up patients
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Advanced Or Metastatic Merkel Cell Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 118 (planned)
- Started
- Dec 11, 2025
- Main results expected
- Mar 31, 2027
- Fully finished
- Dec 30, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR)
Measured over: 12 weeks post-treatment initiation and confirmed on a second response assessment at least 28 days after the initial response assessment
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06947928 · record last updated 2026-04-17 · checked 2026-11-09 15:47 UTC